We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

39 hedge funds and large institutions have $39.2M invested in aTyr Pharma in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more capital invested

Capital invested by funds: $23.1M → $39.2M (+$16M)

0.13% more ownership

Funds ownership: 3.24% → 3.37% (+0.13%)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

25% less funds holding

Funds holding: 52 → 39 (-13)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
39
Holders Change
-13
Holders Change %
-25%
% of All Funds
0.97%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
4
Increased
12
Reduced
12
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$4.3M
2
BlackRock
BlackRock
New York
+$1.82M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$257K
4
DTL
Dynamic Technology Lab
Singapore
+$63.2K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$63.1K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$857K
2
TCM
Tang Capital Management
California
-$601K
3
TAM
Tiverton Asset Management
Delaware
-$205K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$204K
5
Goldman Sachs
Goldman Sachs
New York
-$151K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$12.5M – – –
EC
2
EcoR1 Capital
California
$8.02M +$4.3M +93,976 +135%
PVMCV
3
Polaris Venture Management Co V
Massachusetts
$6.4M – – –
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$2.83M -$857K -18,747 -24%
BlackRock
5
BlackRock
New York
$2.02M +$1.82M +39,821 +2,832%
RSCM
6
Rock Springs Capital Management
Maryland
$1.66M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.52M +$257K +5,613 +22%
GHCM
8
Glen Harbor Capital Management
California
$536K -$86.4K -1,891 -15%
MCIM
9
Meadow Creek Investment Management
Georgia
$442K -$71.2K -1,558 -15%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$392K +$1.46K +32 +0.4%
BCM
11
Bridgeway Capital Management
Texas
$359K – – –
EP
12
Elkfork Partners
Oregon
$347K -$56K -1,225 -15%
RCM
13
Riverhead Capital Management
Delaware
$279K – – –
TAM
14
Tyers Asset Management
Texas
$252K -$40.7K -890 -15%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$204K +$9.14K +200 +5%
Bank of America
16
Bank of America
North Carolina
$167K -$13.3K -291 -8%
Connor, Clark & Lunn Investment Management (CC&L)
17
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$151K +$16K +350 +13%
Renaissance Technologies
18
Renaissance Technologies
New York
$136K +$2.29K +50 +2%
Northern Trust
19
Northern Trust
Illinois
$123K +$47.8K +1,046 +71%
Goldman Sachs
20
Goldman Sachs
New York
$112K -$151K -3,313 -59%
Millennium Management
21
Millennium Management
New York
$103K -$58K -1,269 -38%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$96K – – –
Morgan Stanley
23
Morgan Stanley
New York
$89K +$45.8K +1,002 +124%
QI
24
Quotient Investors
New York
$78K – – –
AIM
25
Alambic Investment Management
California
$78K +$12.4K +272 +21%
1
2

ATYR Hedge Fund Activity: Q1 2017 in Review

39 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2017, worth a combined $39.2M — up 69% from $23.1M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ATYR and 4 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 12 added.

The largest buyer was EcoR1 Capital, adding an estimated $4.3M. The largest seller was Alyeska Investment Group, cutting an estimated $857K.

  • 39 institutional investors held aTyr Pharma (ATYR) as of Q1 2017, down from 52 in Q4 2016.
  • Funds reported $39.2M of aTyr Pharma stock for Q1 2017, up 69% quarter-over-quarter.
  • 4 funds opened new aTyr Pharma positions in Q1 2017 and 11 closed out, a net change of -7 holders.
  • The largest aTyr Pharma buyer in Q1 2017 was EcoR1 Capital, an estimated $4.3M added.
  • The largest aTyr Pharma seller in Q1 2017 was Alyeska Investment Group, an estimated $857K sold.

Based on aggregated 13F filings for Q1 2017.